Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study will assess the performance of the combined system, i.e., the use of the EsoGuard assay on cells collected using the EsoCheck 510(k) cleared device, to detect Barrett's Esophagus, with and without dysplasia, and/or Esophageal Adenocarcinoma, in individuals deemed to be at high risk for these conditions (i.e., screening) per ACG guidelines.
This is a multicenter, single-arm study designed to assess the operating characteristics of the EsoGuard diagnostic assay performed on distal esophageal mucosal cells collected using the EsoCheck cell collection device, compared to the gold standard, for the screening of BE with and without dysplasia and for esophageal adenocarcinoma (EAC), in patients at high risk for BE and for whom a screening EGD is indicated according to ACG-established criteria.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| EsoCheck vs. EGD with or without biopsies | Experimental | All subjects will undergo both the EsoCheck (non-invasive esophageal cell sample collection) followed by EGD (with or without biopsies) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| EsoGuard | Device | EsoGuard assay (LDT) will be used on cells collected using EsoCheck (510K cleared esophageal cell collection device) and compared to results of EGD plus biopsies (when taken) |
| Measure | Description | Time Frame |
|---|---|---|
| Primary Efficacy | The sensitivity and specificity of EsoGuard for the diagnosis of BE on samples collected using EsoCheck, wherein the definitive diagnosis of BE is made by concomitant EGD and biopsy. | Cross-sectional point in time per subject through study completion which is up to approximately 5 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Secondary Efficacy | Negative predictive value (NPV) and positive predictive value (PPV), calculated for the observed prevalence and over a range of prevalences from 1 to 15%. | Cross-sectional point in time per subject through study completion which is up to approximately 5 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Safety of EsoCheck device administration | Assessed by evaluation of AEs/SAEs/ADEs/SADEs/USADEs and Medical Device Deficiency Incidents | Cross-sectional point in time per subject through study completion which is up to approximately 5 weeks |
Inclusion Criteria:
Men aged 50 years old and older
≥5 years either of
No solid foods eaten for at least 2 hours prior to EsoCheck procedure
One or more of the following risk factors:
Caucasian race
Current or past history of cigarette smoking
BMI of at least 30 kg/m2
First-degree relative with BE or EAC
-
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Michelle McDermott | Lucid Diagnostics | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Lucid Investigative Site | Orange | California | 92868 | United States | ||
| Lucid Investigative Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39588974 | Derived | Shaheen NJ, Othman MO, Taunk J, Chang KJ, Jaganmohan S, Yachimski PS, Fang JC, Spataro JS, Verma S, Lee VT, deGuzman BJ, Aklog L. Use of a Two-Gene Methylated DNA Biomarker Assay and Nonendoscopic Balloon for Detection of Barrett Esophagus Among High-Risk Individuals in a Screening Population. Am J Gastroenterol. 2024 Nov 26;120(7):1511-1520. doi: 10.14309/ajg.0000000000003238. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Multicenter, Single Arm
Not provided
Not provided
Not provided
Not provided
| Englewood |
| Colorado |
| 80113 |
| United States |
| Lucid Investigative Site | Naples | Florida | 34102 | United States |
| Lucid Investigative Site | Palm Harbor | Florida | 34684 | United States |
| Lucid Investigative Site | Macon | Georgia | 31201 | United States |
| Lucid Investigative Site | Idaho Falls | Idaho | 83404 | United States |
| Lucid Investigative Site | Rockford | Illinois | 61107 | United States |
| Lucid Investigative Site | New Orleans | Louisiana | 70112 | United States |
| Lucid Investigative Site | Shreveport | Louisiana | 71105 | United States |
| Lucid Investigative Site | Wyoming | Michigan | 49519 | United States |
| Lucid Investigative Site | Flowood | Mississippi | 39232 | United States |
| Lucid Investigative Site | Omaha | Nebraska | 68124 | United States |
| Lucid Investigative Site | New York | New York | 10016 | United States |
| Lucid Investigative Site | Rochester | New York | 14620 | United States |
| Lucid Investigative Site | Chapel Hill | North Carolina | 27599 | United States |
| Lucid Investigative Site | Oklahoma City | Oklahoma | 73102 | United States |
| Lucid Investigative Site | Philadelphia | Pennsylvania | 19107 | United States |
| Lucid Investigative Site | Greenville | South Carolina | 29615 | United States |
| Lucid Investigative Site | Knoxville | Tennessee | 37909 | United States |
| Lucid Investigative Site | Nashville | Tennessee | 37212 | United States |
| Lucid Investigative Site | Houston | Texas | 77030 | United States |
| Lucid Investigative Site | Salt Lake City | Utah | 84132 | United States |
| Lucid Investigative Site | Richmond | Virginia | 23249 | United States |
| Lucid Investigative Site | Richmond | Virginia | 23298 | United States |
| Lucid Investigative Site | Madrid | 28040 | Spain |
| Lucid Investigative Site | Valladolid | 47012 | Spain |
| Lucid Investigative Site | Zaragoza | 50009 | Spain |
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Apr 10, 2024 | May 6, 2024 | 12 |
| ID | Term |
|---|---|
| D001471 | Barrett Esophagus |
| C562730 | Adenocarcinoma Of Esophagus |
| ID | Term |
|---|---|
| D011230 | Precancerous Conditions |
| D009369 | Neoplasms |
| D004935 | Esophageal Diseases |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided